Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...
The Caloocan City government announced on Monday, Feb. 10, that it will offer a week-long free medical check-up at the ...
Alliance Global Partners analyst James Molloy lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $6 from $7.50 and keeps a ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the ...
Irish Examiner on MSN21d
Research finds higher rates of HIV and Hepatitis B in Ireland than previously thoughtA study to determine the extent of such blood-borne infections in the community also found that the prevalence of Hepatitis B and HIV was 'significantly higher' in the Cork region ...
Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...
BJT-778 targets the hepatitis B virus surface antigen. Credit: Orawan Pattarawimonchai/Shutterstock. The US Food and Drug Administration (FDA) has granted ...
About Brelovitug (also known as BJT-778) Brelovitug is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback